FDA Says Safety Concerns May Negate Any Oral Dosing Advantage For GSK’s Anemia Treatment

 
• By Sarah Karlin-Smith
  
illustration of anemia
Safety concerns will dominate GSK advisory panel for oral anemia treatment for chronic kidney disease • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers